PMID- 30390680
OWN - NLM
STAT- MEDLINE
DCOM- 20190708
LR  - 20240403
IS  - 1479-5876 (Electronic)
IS  - 1479-5876 (Linking)
VI  - 16
IP  - 1
DP  - 2018 Nov 3
TI  - Galectin-3 predicts response and outcomes after cardiac resynchronization 
      therapy.
PG  - 299
LID - 10.1186/s12967-018-1675-4 [doi]
LID - 299
AB  - BACKGROUND: Cardiac resynchronization therapy (CRT) reduces symptoms, morbidity 
      and mortality in chronic heart failure patients with wide QRS complexes. However, 
      approximately one third of CRT patients are non-responders. Myocardial fibrosis 
      is known to be associated with absence of response. We sought to see whether 
      galectin-3, a promising biomarker involved in fibrosis processes, could predict 
      response and outcomes after CRT. METHODS: Consecutive patients eligible for 
      implantation of a CRT device with a typical left bundle branch block >/= 120 ms 
      were prospectively included. Serum Gal-3 level, Selvester ECG scoring, and 
      cardiac magnetic resonance with analysis of late gadolinium enhancement (LGE) 
      were ascertained. Response to CRT was defined by a composite endpoint at 
      6 months: no death, nor hospitalization for major cardiovascular event, and a 
      significant decrease in left ventricular end-systolic volume of 15% or more. 
      RESULTS: Sixty-one patients were included (age 61 +/- 5 years, ejection fraction 
      27 +/- 5%), 59% with non-ischemic cardiomyopathy. At 6 months, 49 patients (80%) 
      were considered responders. Responders had a lower percentage of LGE (8 +/- 13% vs 
      22 +/- 16%, p = 0.006), and a trend towards lower rates of galectin-3 (16 +/- 6 ng/mL 
      vs 19 +/- 8 ng/mL, p = 0.13). LGE >/= 14% and Gal-3 >/= 22 ng/mL independently 
      predicted response to CRT (OR = 0.17 [0.03-0.62], p = 0.007, and OR = 0.11 
      [0.02-0.04], p < 0.001, respectively). At 48 months of follow-up, 12 patients had 
      been hospitalized for a major cardiovascular event or had died. Galectin-3 level 
      predicted long-term outcomes (HR = 3.31 [1.00-11.34], p = 0.05). CONCLUSIONS: 
      Gal-3 serum level predicts the response to CRT at 6 months and long-term outcomes 
      in chronic heart failure patients.
FAU - Andre, Clementine
AU  - Andre C
AUID- ORCID: 0000-0003-4052-4047
AD  - Cardiology Department, Trousseau Hospital, University of Tours, 37044, Tours, 
      France. clementine2andre@gmail.com.
FAU - Piver, Eric
AU  - Piver E
AD  - Biochemistry Department, Trousseau Hospital, University of Tours, Tours, France.
FAU - Perault, Romain
AU  - Perault R
AD  - Cardiology Department, Trousseau Hospital, University of Tours, 37044, Tours, 
      France.
FAU - Bisson, Arnaud
AU  - Bisson A
AD  - Cardiology Department, Trousseau Hospital, University of Tours, 37044, Tours, 
      France.
FAU - Pucheux, Julien
AU  - Pucheux J
AD  - Imaging Department, Trousseau Hospital, University of Tours, Tours, France.
FAU - Vermes, Emmanuelle
AU  - Vermes E
AD  - Imaging Department, Trousseau Hospital, University of Tours, Tours, France.
FAU - Pierre, Bertrand
AU  - Pierre B
AD  - Cardiology Department, Trousseau Hospital, University of Tours, 37044, Tours, 
      France.
FAU - Fauchier, Laurent
AU  - Fauchier L
AD  - Cardiology Department, Trousseau Hospital, University of Tours, 37044, Tours, 
      France.
FAU - Babuty, Dominique
AU  - Babuty D
AD  - Cardiology Department, Trousseau Hospital, University of Tours, 37044, Tours, 
      France.
FAU - Clementy, Nicolas
AU  - Clementy N
AD  - Cardiology Department, Trousseau Hospital, University of Tours, 37044, Tours, 
      France.
LA  - eng
PT  - Journal Article
DEP - 20181103
PL  - England
TA  - J Transl Med
JT  - Journal of translational medicine
JID - 101190741
RN  - 0 (Blood Proteins)
RN  - 0 (Galectin 3)
RN  - 0 (Galectins)
RN  - 0 (LGALS3 protein, human)
SB  - IM
MH  - Aged
MH  - Blood Proteins
MH  - *Cardiac Resynchronization Therapy
MH  - Female
MH  - Galectin 3/*blood
MH  - Galectins
MH  - Humans
MH  - Male
MH  - Middle Aged
MH  - Proportional Hazards Models
MH  - Time Factors
MH  - Treatment Outcome
PMC - PMC6215623
OTO - NOTNLM
OT  - Cardiac resynchronization therapy
OT  - Galectin-3
OT  - Heart failure
EDAT- 2018/11/06 06:00
MHDA- 2019/07/10 06:00
PMCR- 2018/11/03
CRDT- 2018/11/05 06:00
PHST- 2018/07/19 00:00 [received]
PHST- 2018/10/27 00:00 [accepted]
PHST- 2018/11/05 06:00 [entrez]
PHST- 2018/11/06 06:00 [pubmed]
PHST- 2019/07/10 06:00 [medline]
PHST- 2018/11/03 00:00 [pmc-release]
AID - 10.1186/s12967-018-1675-4 [pii]
AID - 1675 [pii]
AID - 10.1186/s12967-018-1675-4 [doi]
PST - epublish
SO  - J Transl Med. 2018 Nov 3;16(1):299. doi: 10.1186/s12967-018-1675-4.